作者
Gopal Gawhale*, Ganesh Gore, Dr. Ashish Gawai, Dr. Shirish Jain
摘要
Nitrosamine impurities have become one of the most significant pharmaceutical quality and safety concerns since 2018, following widespread detection across multiple therapeutic classes. These genotoxic compounds are potent carcinogens with extremely low acceptable intake limits, generally between 26.6 and 96 nanograms per day, as established under International Council for Harmonization M7 guidelines. Since the discovery of a nitrosamine contaminant in valsartan products manufactured by a Chinese supplier in 2018, regulatory agencies worldwide, including the United States Food and Drug Administration and the European Medicines Agency, have introduced stringent control frameworks and guidance documents. Contamination has since extended beyond angiotensin receptor blockers to metformin, ranitidine, and numerous other drug classes including antimycobacterials, histamine receptor antagonists, statins, ACE inhibitors, anticoagulants, and antidiabetic agents. Modern analytical approaches, particularly liquid chromatography coupled with tandem mass spectrometry, gas chromatography–mass spectrometry, and high-resolution mass spectrometry, now allow detection at sub-parts-per-billion levels with high selectivity. This article reviews nitrosamine chemistry and formation mechanisms, global regulatory frameworks, analytical method development and validation practices, risk assessment methodology, and control strategies applied across the pharmaceutical product lifecycle. The integration of analytical expertise, quality risk management, and regulatory compliance is presented as essential to protecting patient safety while sustaining medicine availability